inclusion criteria: 1. adult male or female individuals of ≥18 years old. 2. in women of childbearing potential, negative pregnancy test at inclusion/baseline visit. 3. has confirmed sars-cov-2 infection as determined by pcr, a validated naat (i.e., genexpert), or validated antigen rapid diagnostic test from nasopharyngeal swabs ≤5 days prior to inclusion/baseline visit. 4. symptomatic with mild covid-19 with symptoms onset date ≤ 7 days prior to inclusion/baseline visit. mild covid-19, as defined per nih: individuals who have any of the common signs and/or symptoms of covid-19 (i.e., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnoea, or abnormal chest imaging. 5. willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study. 6. has understood the information provided and capable of giving informed consent.

inclusion criteria: 1. adult male or female individuals of ≥18 years old. 2. in women of childbearing potential, negative pregnancy test at inclusion/baseline visit. 3. has confirmed sars-cov-2 infection as determined by pcr, a validated naat (i.e., genexpert), or validated antigen rapid diagnostic test from nasopharyngeal swabs ≤5 days prior to inclusion/baseline visit. 4. symptomatic with mild covid-19 with symptoms onset date ≤ 7 days prior to inclusion/baseline visit. mild covid-19, as defined per nih: individuals who have any of the common signs and/or symptoms of covid-19 (i.e., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnoea, or abnormal chest imaging. 5. willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study. 6. has understood the information provided and capable of giving informed consent.

inclusion criteria: adult male or female individuals of ≥18 years old. in women of childbearing potential, negative pregnancy test at inclusion/baseline visit. has confirmed sars-cov-2 infection as determined by pcr, a validated naat (i.e., genexpert), or validated antigen rapid diagnostic test from nasopharyngeal swabs ≤5 days prior to inclusion/baseline visit. symptomatic with mild covid-19 with symptoms onset date ≤ 7 days prior to inclusion/baseline visit. mild covid-19, as defined per nih: individuals who have any of the common signs and/or symptoms of covid-19 (i.e., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnoea, or abnormal chest imaging. willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study. has understood the information provided and capable of giving informed consent.

inclusion criteria: adult male or female individuals of ≥18 years old. in women of childbearing potential, negative pregnancy test at inclusion/baseline visit. has confirmed sars-cov-2 infection as determined by pcr, a validated naat (i.e., genexpert), or validated antigen rapid diagnostic test from nasopharyngeal swabs ≤5 days prior to inclusion/baseline visit. symptomatic with mild covid-19 with symptoms onset date ≤ 7 days prior to inclusion/baseline visit. mild covid-19, as defined per nih: individuals who have any of the common signs and/or symptoms of covid-19 (i.e., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnoea, or abnormal chest imaging. willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study. has understood the information provided and capable of giving informed consent.